Challenges in studying transient protein-protein interactions for drug development and how to overcome them

From signal transduction to transcriptional regulation, protein-protein interactions (PPIs) form the basis of virtually every biological process and are major players in the dynamic game of life.  

Over the past two decades, PPIs – particularly transient ones – have attracted growing attention as drug targets,¹ thanks to their critical roles in biological regulation and disease. Despite their biological importance, transient protein interactions remain one of the most underexplored areas in drug discovery, largely because they are exceptionally difficult to detect and study.² 

The challenge lies in their inherent nature. Transient PPIs are often weak, with dissociation constants in the micromolar range, short-lived (lifetimes of seconds or less), and highly context-dependent.² Most existing methods for PPI analysis, while robust for stable protein complexes, fail to capture these fleeting molecular encounters, let alone begin to characterize their dynamics. 

Depixus MAGNA One™ changes that. By enabling the real-time detection of thousands of individual transient PPIs, it brings into focus a crucial class of interactions that have, until now, remained largely invisible. 

What are transient protein-protein interactions and why are they biologically important?

While stable PPIs dominate structural biology textbooks, transient interactions are increasingly being recognized as biologically significant – especially in dynamic cellular processes. 

Some of the essential events governed by transient PPIs include:  

• Signal transduction (e.g. receptor-effector or kinase-substrate interactions) 
• Protein trafficking (e.g. chaperone-substrate recognition) 
• Pathogen-host interactions (e.g. transient hijacking of cellular proteins)

Transient protein-protein interactions are often mediated by intrinsically disordered regions,³ modulated by post-translational modifications (PTMs), and highly dependent on spatiotemporal cellular contexts.

Though short-lived, they are biologically significant and evolutionarily conserved. In fact, a recent analysis suggests that disrupting most transient PPIs is as deleterious as disrupting stable ones, implying similar levels of selective constraint across the human interactome.⁴

Disproportionate to their biological relevance, transient PPIs remain an underutilized space in drug discovery, particularly for cutting-edge applications such as molecular glues that aim to stabilize or induce novel interactions.

Why current techniques for detecting transient protein-protein interactions fall short

The analytical toolbox for PPIs is vast, ranging from low-throughput biochemical assays to high-throughput screens and computational predictions.⁵

However, the weak affinities and rapid dissociation of transient PPIs make them notoriously difficult to capture using conventional tools. And those that do manage to capture the existence of these brief interactions through chemical cross-linking techniques are unable to resolve the dynamic nature of transient PPIs.

Even tandem affinity purification followed by MS (TAP-MS), a staple for PPI mapping, tends to lose transient protein complex partners during washing steps unless combined with chemical crosslinking, which comes at the cost of dynamic resolution and scalability.

The table below compares some of the current approaches for analyzing transient protein-protein interactions and their limitations.^2,5

Computational methods have become increasingly important in mapping potential PPIs, and are particularly useful for filling gaps left by experimental limitations.⁶

However, these approaches are only predictive and depend on high-quality training data, which is often biased towards stable interactions. This means they are not a full substitute for experimental validation, especially for dynamic and condition-specific interactions such as transient PPIs.

In summary, most analytical methods can tell us whether two proteins interact, but rarely how, when, and for how long. Yet for transient PPIs, these parameters are precisely where their biological relevance lies.

Depixus MAGNA One: Real-time, single-molecule analysis of transient PPIs

Depixus MAGNA One addresses these limitations by enabling non-destructive, real-time monitoring of individual protein–protein interactions at scale.

Based on magnetic force spectroscopy (MFS), Depixus MAGNA One captures dynamic interactions between thousands of individual pairs of proteins over the course of minutes or even hours.

Depixus MAGNA One can analyze PPIs lasting just a few seconds – well within the kinetic window of transient interactions. It can also detect weak interactions, as well as measuring key biophysical parameters such as binding kinetics, interaction duration and relative binding affinities.

Unlike ensemble-based methods such as SPR that average out binding behavior across millions of molecules, Depixus MAGNA One can detect rare events and heterogeneous behavior.

The platform allows researchers to quantify not just whether two proteins bind, but the dynamics of their interaction and how it can be modulated using small molecules or other ligands.

The large scale single molecule resolution offered by Depixus MAGNA One is essential not just for advancing understanding of molecular biology, but for drug discovery efforts targeting weak, context-specific protein interactions with molecules such as molecular glues.

Accelerating protein-protein interaction research and drug discovery

Transient protein-protein interactions are a rich but under-characterized layer of biological complexity. While existing techniques have revealed much about stable complexes, the most dynamic and functionally responsive interactions remain elusive due to the limitations of these methods.

Traditional biophysical and proteomic techniques are too blunt or static. Computational tools offer predictive power but require experimental grounding. The field needs new tools that can track these fleeting molecular conversations as they really happen.

By enabling detailed, dynamic analysis of individual biomolecular interactions at scale, Depixus MAGNA One reveals a new dimension to protein-protein interactions and opens fresh avenues for targeted drug development.

Want to see biology as it really happens? Talk to our team to learn more about Depixus MAGNA One: info@depixus.com

References:

1. Shin WH, et al. Current Challenges and Opportunities in Designing Protein-Protein Interaction Targeted Drugs. Adv Appl Bioinform Chem. 2020 Nov 12;13:11-25. doi: 10.2147/AABC.S235542.
2. Perkins JR, et al. Transient protein-protein interactions: structural, functional, and network properties. Structure. 2010 Oct 13;18(10):1233-43. doi: 10.1016/j.str.2010.08.007.
3. Hosoya Y, Ohkanda J. Intrinsically Disordered Proteins as Regulators of Transient Biological Processes and as Untapped Drug Targets. Molecules. 2021 Apr 7;26(8):2118. doi: 10.3390/molecules26082118
4. Ghadie MA, Xia Y. Are transient protein-protein interactions more dispensable? PLoS Comput Biol. 2022 Apr 11;18(4):e1010013. doi: 10.1371/journal.pcbi.1010013
5. Akbarzadeh S, Coşkun Ö, Günçer B. Studying protein-protein interactions: Latest and most popular approaches. J Struct Biol. 2024 Dec;216(4):108118. doi: 10.1016/j.jsb.2024.108118
6. Grassmann G, Miotto M, Desantis F, Di Rienzo L, Tartaglia GG, Pastore A, Ruocco G, Monti M, Milanetti E. Computational Approaches to Predict Protein-Protein Interactions in Crowded Cellular Environments. Chem Rev. 2024 Apr 10;124(7):3932-3977. doi: 10.1021/acs.chemrev.3c00550